Fischer Medical Ventures Ltd
Incorporated in 1993, Fischer Chemic Ltd does trading of chemicals and machineries[1]
- Market Cap ₹ 5,415 Cr.
- Current Price ₹ 849
- High / Low ₹ 919 / 454
- Stock P/E 2,417
- Book Value ₹ 15.2
- Dividend Yield 0.00 %
- ROCE 5.25 %
- ROE 4.55 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 55.7 times its book value
- Promoter holding has decreased over last quarter: -12.1%
- Earnings include an other income of Rs.1.42 Cr.
- Company has high debtors of 398 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|
0.18 | 20.98 | 82.32 | |
0.16 | 19.12 | 78.98 | |
Operating Profit | 0.02 | 1.86 | 3.34 |
OPM % | 11.11% | 8.87% | 4.06% |
0.00 | 0.50 | 1.42 | |
Interest | 0.02 | 0.07 | 0.30 |
Depreciation | 0.00 | 0.18 | 1.31 |
Profit before tax | 0.00 | 2.11 | 3.15 |
Tax % | 12.80% | ||
-0.04 | 1.84 | 2.47 | |
EPS in Rs | -2.33 | 0.34 | 0.46 |
Dividend Payout % | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 11556% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 4700% |
Stock Price CAGR | |
---|---|
10 Years: | 72% |
5 Years: | 80% |
3 Years: | 141% |
1 Year: | 77% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|
Equity Capital | 0.17 | 53.50 | 53.50 |
Reserves | -0.44 | 27.61 | 27.95 |
0.57 | 1.68 | 1.47 | |
0.05 | 3.53 | 57.80 | |
Total Liabilities | 0.35 | 86.32 | 140.72 |
0.00 | 14.71 | 14.87 | |
CWIP | 0.00 | 0.00 | 2.89 |
Investments | 0.00 | 1.21 | 11.70 |
0.35 | 70.40 | 111.26 | |
Total Assets | 0.35 | 86.32 | 140.72 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | |
---|---|---|
-7.59 | ||
-28.61 | ||
37.11 | ||
Net Cash Flow | 0.91 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | |
---|---|---|
Debtor Days | 344.72 | 397.88 |
Inventory Days | ||
Days Payable | ||
Cash Conversion Cycle | 344.72 | 397.88 |
Working Capital Days | 324.44 | 505.40 |
ROCE % | 5.25% |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
12h - Company states it does not qualify as large entity under SEBI debt issuance norms, no borrowings outstanding.
-
Announcement Under Regulation 30
23 Apr - Subsidiary invests USD 12.5M for 15% stake in Singapore biomedical tech firm Nanomedic.
-
Announcement Under Regulation 30 - Intimation Of Receipt Of Central Government Approval
23 Apr - Appointment of Ravindran Govindan as Managing Director for 5 years from Jan 31, 2025.
-
Announcement Under Regulation 30
21 Apr - Subsidiary invests USD 12.5M for 15% stake in Nanomedic Technologies for business expansion.
-
Announcement Under Regulation 30
21 Apr - FMV invests $1M for 60% in Fischer Hospitality and $0.5M for 1.7% in Obelabs with exclusive distribution rights.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Dec 2024TranscriptNotesPPT
Business Overview:[1]
Company is in the business of processing, manufacturing and trading of Laboratory Grade Chemicals